Julien Maziéres, MD, PhD


Dr. Maziéres on the Evaluation of Tepotinib Plus Osimertinib in EGFR-mutated NSCLC

Julien Maziéres, MD, PhD, discusses the evaluation of tepotinib plus osimertinib in EGFR-mutated non­–small cell lung cancer.

Mattia Garutti, MD


Dr. Garutti on the Potential Shift to Neoadjuvant Therapy in Melanoma

Mattia Garutti, MD, discusses the potential shift to neoadjuvant therapy in melanoma.

Daniel Pollyea, MD, MS


Review of the SELECT-AML-1 Trial and the Future of Newly Diagnosed AML

Daniel Pollyea, MD, MS, reviews the ongoing SELECT-AML-1 trial and comments on novel therapies and biomarkers in patients with newly diagnosed unfit AML.

Arun Azad, PhD


Dr. Azad on the Significance of the PROfound Trial in mCRPC

Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.

Caroline Farrington, PhD


Dr. Farrington on the Importance of Genetic Testing in CRC

Caroline Farrington, PhD, discusses the importance of genetic testing in colorectal cancer.

Shahab Babakoohi, MD


Basal Cell Carcinoma Clinical Pearls

Drs Babakoohi and Atlas share clinical pearls for community oncologists on treating basal cell carcinoma.

Su H. Wang, MD, MPH


Dr. Wang on the Rationale for Viral Hepatitis Screening to Prevent HCC

Su H. Wang, MD, MPH, discusses the rationale for the integration of viral hepatitis screening and care in a hospital system as the first steps for preventing liver cancers like hepatocellular carcinoma.

Jeremy C. Jones, MD


Dr. Jones on the Importance of Immune Checkpoint Inhibitors in CRC

Jeremy C. Jones, MD, discusses key lessons learned from the phase 3 KEYNOTE-177 trial.

John Lister, MD


Dr. Lister on Selecting Patients With Lymphoma for CAR T-Cell Therapy

John Lister, MD, discusses selecting patients with lymphoma for CAR T-cell therapy.

Paul L. Nguyen, MD


Dr. Nguyen on Treatment Considerations in High-Risk Prostate Cancer

Paul L. Nguyen, MD, discusses treatment considerations in high-risk prostate cancer.

Mark Fleury, PhD


Dr. Fleury on the Advancement of Decentralized Clinical Trials During COVID-19

Mark Fleury, PhD, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.

Rana R. McKay, MD, University of California, San Diego


Dr. McKay on the Rationale for Triplet Frontline Therapy in RCC

Rana R. McKay, MD, discusses the pros and cons of utilizing triplet therapy in the frontline treatment of patients with renal cell carcinoma.

Shanu Modi, MD


Dr. Modi on Trastuzumab Deruxtecan in HER2-low Breast Cancer

Shanu Modi, MD, discusses the significance of the FDA approval of the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-low breast cancer.

Karam Al-Issa, MD


Student Loan Debt, Immigration Status Often Drive Career Decisions for Fellows

Investigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.

Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College


Testing for PSMA in Community Settings

Scott T. Tagawa, MD, MS, FACP, discusses integration of prostate-specific membrane antigen [PSMA] positron emission tomography [PET] imaging into community practice to help identify potential candidates for PSMA-targeted radioligand therapy.

Amit Patel, BSc, MBBS, PhD, The Christie NHS Foundation Trust


Research on CAR T Therapy in Earlier Lines of Treatment

Amit Patel, BSc, MBBS, PhD, discusses currently ongoing clinical trials of CAR T-cell therapy in first- and second-line treatment settings and comments on potential developments on the horizon.

Evandro D. Bezerra, MD


Dr. Bezerra on Barriers to Enrollment for Clinical Trials in B-Cell NHL

Evandro D. Bezerra, MD, discusses barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma who have progressed on anti-CD19 CAR T-cell therapy.

James A. DeCaprio, MD


Dr. DeCaprio on Raising Awareness in Merkel Cell Carcinoma

James A. DeCaprio, MD, discusses raising awareness in Merkel cell carcinoma.

Inhye Ahn, MD


Dr. Ahn on Choosing Between Treatment Options in CLL

Inhye Ahn, MD, physician, discusses choosing between treatment options in chronic lymphocytic leukemia.

Uwe Platzbecker, MD


First-Line Treatment Options for Lower-Risk MDS

Thomas Cluzeau, MD, PhD provides an overview of first-line treatment options for symptomatic anemia in patients with lower-risk MDS, followed by a discussion of panelists’ treatment patterns and dosing strategies across the globe.

Aurélien Marabelle, MD, PhD


Dr. Marabelle on Preliminary Findings With SO-C101 in Advanced Solid Tumors

Aurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.

Karim Chamie, MD


Dr. Chamie on Examining N-803 Plus BCG in BCG-Unresponsive NMIBC CIS

Karim Chamie, MD, discusses the design of the phase 2/3 QUILT-3.032 trial in patients with Bacillus Calmette-Guerín–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.

Ulka N. Vaishampayan, MBBS, FAB


Dr. Vaishampayan on the Rationale of the PROBE Trial in RCC

Ulka Nitin Vaishampayan, MBBS, discusses the rationale of the phase 3 PROBE trial in advanced renal cell carcinoma.

Wen Wee Ma, MBBS


Dr. Ma on First-Line Treatment Considerations in Metastatic Pancreatic Cancer

Wen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.

Hannah Choe, MD


Steroid Refractory Acute GvHD and REACH Trials

An overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.

Alexander E. Perl, MD, University of Pennsylvania


Future Treatment Landscape of AML

Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.

David Planchard, MD, PhD, Gustave Roussy Institute of Oncology


Dr. Planchard on the Benefit of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

David Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).

Michelle Melisko, MD


Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer

Closing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.

Gretchen G. Kimmick, MD, MS


Dr. Kimmick on Selecting Adjuvant Therapy for Patients With HER2+ Breast Cancer

Gretchen G. Kimmick, MD, MS, discusses selecting adjuvant therapy for patients with HER2-positive breast cancer.

Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute


ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.